{{medical}}
[[File:Carbapenems_structure.svg|缩略图]]
'''碳青黴烯'''（Carbapenem）是一類廣效性[[抗生素|抗生素]]的總稱，通常被作為後線抗生素使用，治療嚴重的細菌感染。這類抗生素通常僅被用在多重[[抗生素抗藥性|抗藥性]]（MDR）細菌的治療上。碳青黴烯和[[盤尼西林|盤尼西林]]、[[頭孢菌素|頭孢菌素]]等同為[[β-內醯胺類抗生素|β-內醯胺類抗生素]]，作用機制為干擾[[細胞壁|細胞壁]]之[[肽聚糖|肽聚糖]]的合成。不過碳青黴烯比起另外兩者而言，具備更為廣效的殺菌性，且其通常也不會被[[β-內醯胺酶|β-內醯胺酶]]分解。 

第一種碳青黴烯類抗生素是[[默克大藥廠|默克大藥廠]]開發的{{tsl|en|thienamycin}}，其源自''{{tsl|en|Streptomyces cattleya}}''<ref>{{Cite book|title=Drug Discovery-A History|last=Sneader|first=Walter|publisher=Wiley|year=2006|isbn=978-0-471-89980-8|page=310}}</ref><ref>{{Cite journal|title=Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin|date=June 1985|journal=[[American_Journal_of_Medicine|American Journal of Medicine]]|issue=6A|doi=10.1016/0002-9343(85)90097-X|volume=78|pages=3–21|issn=0002-9343|pmid=3859213}}</ref>。近年來，[[克雷伯氏肺炎菌|克雷伯氏肺炎菌]]、{{tsl|en|Enterobacteriaceae|腸內細菌科}}等微生物逐漸演化出抗藥性。對一類後線抗生素具有抗藥性將使其難以被任何抗生素治癒<ref>{{Cite web|url=http://outbreaknewstoday.com/brazil-klebsiella-pneumoniae-carbapenemase-prompts-closing-of-hospital-icu-51544/|title=Brazil: Klebsiella pneumoniae carbapenemase prompts closing of hospital ICU - Outbreak News Today}}</ref><ref name="Carbapenems">{{Cite journal|title=Carbapenems|journal=J Chemother|issue=1|doi=10.1179/1973947812Y.0000000032|year=2013|volume=25|pages=1–17|pmid=23433439}}</ref><ref name="ReferenceA">{{Cite journal|title=Carbapenems: past, present, and future|journal=Antimicrob. Agents Chemother.|issue=11|doi=10.1128/AAC.00296-11|year=2011|volume=55|pages=4943–60|pmc=3195018|pmid=21859938}}</ref><ref>{{Cite journal|title=Carbapenemases: a problem in waiting?|date=October 2000|journal=[[Current_Opinion_in_Microbiology|Current Opinion in Microbiology]]|issue=5|doi=10.1016/S1369-5274(00)00128-4|volume=3|pages=489–95|issn=1369-5274|pmid=11050448}}</ref>。

== 參考資料 ==
{{Reflist|30em}}

{{Template:细胞壁破坏性抗生素}}
[[Category:碳青黴烯|Category:碳青黴烯]]